|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase IV
|
|
|
|
Natural history/Epidemiology
|
|
|
|
Completed
|
|
|
|
No age specified
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
D791AL00002 V-15-33, OZV1533, NCT00252759
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase IV
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
19 to 80
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
D7913L00067 NCT00608868
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III, Phase II
|
|
|
|
Treatment
|
|
|
|
Completed
|
|
|
|
18 to5
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
1839IL/0143 NCT00234429
|
|
|
|
|
|
|
|
Last Modified: 7/1/2001  First Published: 7/1/2000 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
ZENECA-1839IL/0014 NCT00006048
|
|
|
|
|
|
|
|
Last Modified: 7/1/2001  First Published: 7/1/2000 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
ZENECA-1839IL/0017 MSKCC-00100, NCT00006049
|
|
|
|
|
|
|
|
Last Modified: 4/4/2008  First Published: 7/1/2001 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
Not specified
|
|
|
|
NCI
|
|
|
|
SWOG-S0023 CAN-NCIC-BR15, NCCTG-S0023, S0023, NCT00020709, BR15
|
|
|
|
|
|
|
|
Last Modified: 1/25/2008  First Published: 11/1/2002 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
NCI, Other
|
|
|
|
CAN-NCIC-BR19 ECOG-CAN-NCIC-BR19, SWOG-CAN-NCIC-BR19, NCIC-BR.19, NCT00049543, BR19
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Completed
|
|
|
|
18 and over
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
TLK286.3020 NCT00080340
|
|
|
|
|
|
|
|
Last Modified: 7/28/2008  First Published: 8/24/2004 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
Other
|
|
|
|
EORTC-08021 ILCP-01/03, EUDRACT-2004-001331-36, NCT00091156
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
Other
|
|
|
|
SCRI UNKPRI 12 IRUSIRES0215, CPTAIV-0020-417, B9E-US-X423, NCT00193596
|
|
|
|